Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Up – What’s Next?

Rapport Therapeutics (NASDAQ:RAPP)’s stock price gapped up prior to trading on Friday . The stock had previously closed at $24.53, but opened at $25.62. Rapport Therapeutics shares last traded at $25.02, with a volume of 2,436 shares.

Rapport Therapeutics Trading Up 3.4 %

The company has a fifty day moving average of $21.85.

Rapport Therapeutics (NASDAQ:RAPP) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($1.02). On average, analysts anticipate that Rapport Therapeutics will post -3.46 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Values First Advisors Inc. bought a new stake in Rapport Therapeutics during the third quarter valued at about $31,000. SG Americas Securities LLC bought a new stake in shares of Rapport Therapeutics during the third quarter valued at approximately $101,000. Sandia Investment Management LP purchased a new position in Rapport Therapeutics during the second quarter valued at $116,000. Davidson Kempner Capital Management LP bought a new stake in shares of Rapport Therapeutics in the second quarter worth about $229,000. Finally, Squarepoint Ops LLC bought a new stake in Rapport Therapeutics during the second quarter worth approximately $380,000.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.